{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:12:59Z","timestamp":1731388379365,"version":"3.28.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,11]]},"DOI":"10.7759\/cureus.73444","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T15:11:58Z","timestamp":1731337918000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor-Induced Myositis Causing Severe Ptosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Nadine A","family":"Abdeljabbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed  B","family":"Haradwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjamalai","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49007","article-title":"Immune checkpoint inhibitor-induced myositis\/myasthenia gravis overlap","volume":"15","author":"Gosser C","year":"2023","unstructured":"Gosser C, Al Bawaliz A, Bahaj W, Chesney J, Ranjan S. Immune checkpoint inhibitor-induced myositis\/myasthenia gravis overlap. Cureus. 2023, 15:e49007. 10.7759\/cureus.49007","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds KL","year":"2019","unstructured":"Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019, 24:435-43. 10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"ref3","unstructured":"FDA. Oncology (cancer)\/hematologic malignancies approval notifications. (2024). Accessed: November 11, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notif."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja L","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015, 3:36. 10.1186\/s40425-015-0078-9","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:1756286418799864. 10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth P","year":"2021","unstructured":"Roth P, Winklhofer S, M\u00fcller AM, et al.. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021, 97:102189. 10.1016\/j.ctrv.2021.102189","journal-title":"Cancer Treat Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: toxicities and management","volume":"35","author":"Hahn AW","year":"2017","unstructured":"Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017, 35:701-7. 10.1016\/j.urolonc.2017.08.005","journal-title":"Urol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.12.005","article-title":"The co-existence of myasthenia gravis in patients with myositis: a case series","volume":"43","author":"Paik JJ","year":"2014","unstructured":"Paik JJ, Corse AM, Mammen AL. The co-existence of myasthenia gravis in patients with myositis: a case series. Semin Arthritis Rheum. 2014, 43:792-6. 10.1016\/j.semarthrit.2013.12.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P3.4-008","article-title":"Pembrolizumab induced myositis (P3.4-008)","volume":"92","author":"Elkhider H","year":"2019","unstructured":"Elkhider H, Williams H, Ibrahim F, Dhall R. Pembrolizumab induced myositis (P3.4-008). Neurology. 2019, 92:3-4. 10.1212\/WNL.92.15_supplement.P3.4-008","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28330","article-title":"A challenging case of eyelid ptosis and diplopia induced by pembrolizumab","volume":"14","author":"Garcez D","year":"2022","unstructured":"Garcez D, Clara AI, Moraes-Fontes MF, Marques JB. A challenging case of eyelid ptosis and diplopia induced by pembrolizumab. Cureus. 2022, 14:e28330. 10.7759\/cureus.28330","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010130","article-title":"Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series","volume":"12","author":"Marco C","year":"2022","unstructured":"Marco C, Sim\u00f3 M, Alemany M, et al.. Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series. J Clin Med. 2022, 12:10.3390\/jcm12010130","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1090820X10374108","article-title":"Evaluation and management of unilateral ptosis and avoiding contralateral ptosis","volume":"30","author":"Zoumalan CI","year":"2010","unstructured":"Zoumalan CI, Lisman RD. Evaluation and management of unilateral ptosis and avoiding contralateral ptosis. Aesthet Surg J. 2010, 30:320-8. 10.1177\/1090820X10374108","journal-title":"Aesthet Surg J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/303336-immune-checkpoint-inhibitor-induced-myositis-causing-severe-ptosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T15:12:01Z","timestamp":1731337921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/303336-immune-checkpoint-inhibitor-induced-myositis-causing-severe-ptosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.73444","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}